1. NLS Pharmaceutics raised $3 million through equity financing. 2. Funds support merger with Kadimastem and working capital needs. 3. Investor confidence remains high following financing completion. 4. The merger is subject to regulatory and shareholder approvals. 5. Kadimastem focuses on treatments for ALS and diabetes.
The successful fundraising indicates strong investor confidence, which can positively impact NLSP’s stock price, similar to past successful financings in biotech firms that led to stock rallies.
The successful equity financing and merger with Kadimastem are crucial for NLSP’s future, making the news highly relevant and impactful.
The immediate funds will enhance NLSP's merger prospects, likely leading to optimistic trading in the near term as investors anticipate potential growth from the merger.
ZÜRICH, June 30, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd. (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced that it has completed the second and final $1 million closing of its previously disclosed $3 million equity financing of preferred shares (or equivalents) and warrants from March 2025.
Pursuant to the second closing, the Company agreed to issue 606,061 preferred shares (or equivalent) at a conversion price of $1.65 per share, representing a 10% premium to the market share price on the date the original agreement was signed (March 28, 2025). The second closing occurred on June 27, 2025.